Isolasi Dan Karakterisasi Bakteri Endofit Penghasil Inhibitor α-Glukosidase Dari Tanaman Pare (Momordica Charantia L)

Diabetes merupakan penyakit metabolik yang serius di Indonesia. Jumlah penderita diabetes mengalami peningkatan setiap tahunnya. Inhibitor α-glukosidase merupakan senyawa yang dapat menghambat enzim α-glukosidase sehingga bermanfaat sebagai obat antidiabetes. Tanaman Pare (Momordica charantia) diketahui memiliki kasiat sebagai anti diabetes. Senyawa aktif yang dihasilkan tanaman tersebut dapat berasal dari endofit yang hidup di dalam jaringan tanaman. Eksplorasi bakteri endofit dari tanaman pare merupakan salah satu cara untuk mendapatkan isolat bakteri penghasil inhibitor enzim α-glukosidase. Isolasi bakteri dilakukan dengan menginokulasikan sampel tanaman yang telah disterilisasi permukaan pada media agar. Isolat bakteri yang didapat selanjutnya dimurnikan dan di karakterisasi lebih lanjut baik morfologi maupun aktivitas inhibitor α-glukosidasenya. Pengujian aktivitas inhibitor α-glukosidase menggunakan metode spektrofotometer dengan nitrofenil-α-D-glukopiranosida sebagai substrat. Hasil penelitian diperoleh 5 isolat bakteri endofit penghasil inhibior α-glukosidase. Penghambatan terbesar ditunjukkan oleh isolat bakteri Ad 1 yaitu sebesar 27,4%

<em>CYP2D6 </em>genotype and adjuvant tamoxifen:meta-analysis of heterogeneous study populations

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1), CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.</p

How to write an ICS/IUGA conference abstract

Contains fulltext : 88292.pdf (publisher's version ) (Closed access)INTRODUCTION: This article aims to condense the lectures and discussions from workshops on good reporting at IUGA Como 2009 and ICS San Francisco 2009, providing practical advice for the novice researcher summarising their data for the first time. CONCLUSIONS: Drafting an abstract can be a time consuming process. Formal guidance, such as CONSORT and STROBE, exists for the kinds of information that should be included regarding almost all designs of clinical trials. Follow the abstract submission rules closely to avoid outright rejection. Plan to highlight the novelty, scientific merit and clinical impact of the work. Try not to overstate the importance of the findings. Do not forget to publish the work in a peer reviewed journal.1 mei 201